Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

NCT07035093 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07035093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07035093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 29, 2025
Completion date
September 30, 2027
Enrollment
586 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

chronic low back pain (clbp), obesity, overweight